Filter Specialty
Submit To The Journals

Foreword – European Ophthalmic Review, 2016;10(1):13

European Ophthalmic Review, 2016;10(1):13

Welcome to the latest edition of European Ophthalmic Review, which features a wide range of articles, beginning with intraocular diseases. An editorial from Rodrigues and Lim explores approaches to achieving successful outcomes and minimising complications in neovascular glaucoma surgery. Also on the subject of glaucoma, Feijoo discusses the latest advances in tonometry. Biologic targeted therapies are transforming the treatment of uveitis. Taylor discusses the latest clinical advances in this field.

Optical coherence tomography angiography (OCTA) is an emerging, non-invasive imaging technique that generates three-dimensional images without the need for intravenous dyes. This technology has numerous potential applications for retinal vascular disease. Turgut and Reznicek each present reviews of the advantages and disadvantages of OCTA. In addition, Iuliano describes the application of OCTA to chorodial neovascularisations.

Diabetic macular oedema continues to present a major health challenge worldwide. Augustin presents a review of findings from clinical trials and real-world studies. While clinical trial data have shown comparable outcomes between vascular endothelial growth factor (VEGF) inhibitors and corticosteroids, real-world findings suggest that lower injection frequencies of VEGF are associated with less impressive outcomes. Sustained delivery of corticosteroids has shown similar efficacy in clinical and real-world studies.

Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly. In an expert review of a symposium presented at the 15th EURETINA Congress, Korobelnik et al discuss the use of aflibercept in AMD, including recent real-world data indicating that aflibercept can be given with reduced dosing frequency.

Finally, Michels and Wirth present an update of the management of branch retinal vein occlusion, including established and emerging treatment options.

European Ophthalmic Review would like to thank our Editorial Board for their continuing support and guidance. A special thanks also goes to our authors, who gave their time and effort to produce an insightful selection of articles. The expert discussions and the range of topics covered ensure there is something of interest for every reader and we hope you find this edition useful.

  • Touch Medical Media Limited, trading as Touch Medical Media, is a private limited company registered in England and Wales at The White House, Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. © 2019 All rights reserved.

    touchOphthalmology is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.